Back to Search Start Over

Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control.

Authors :
Gideon HP
Hughes TK
Tzouanas CN
Wadsworth MH 2nd
Tu AA
Gierahn TM
Peters JM
Hopkins FF
Wei JR
Kummerlowe C
Grant NL
Nargan K
Phuah JY
Borish HJ
Maiello P
White AG
Winchell CG
Nyquist SK
Ganchua SKC
Myers A
Patel KV
Ameel CL
Cochran CT
Ibrahim S
Tomko JA
Frye LJ
Rosenberg JM
Shih A
Chao M
Klein E
Scanga CA
Ordovas-Montanes J
Berger B
Mattila JT
Madansein R
Love JC
Lin PL
Leslie A
Behar SM
Bryson B
Flynn JL
Fortune SM
Shalek AK
Source :
Immunity [Immunity] 2022 May 10; Vol. 55 (5), pp. 827-846.e10. Date of Electronic Publication: 2022 Apr 27.
Publication Year :
2022

Abstract

Mycobacterium tuberculosis lung infection results in a complex multicellular structure: the granuloma. In some granulomas, immune activity promotes bacterial clearance, but in others, bacteria persist and grow. We identified correlates of bacterial control in cynomolgus macaque lung granulomas by co-registering longitudinal positron emission tomography and computed tomography imaging, single-cell RNA sequencing, and measures of bacterial clearance. Bacterial persistence occurred in granulomas enriched for mast, endothelial, fibroblast, and plasma cells, signaling amongst themselves via type 2 immunity and wound-healing pathways. Granulomas that drove bacterial control were characterized by cellular ecosystems enriched for type 1-type 17, stem-like, and cytotoxic T cells engaged in pro-inflammatory signaling networks involving diverse cell populations. Granulomas that arose later in infection displayed functional characteristics of restrictive granulomas and were more capable of killing Mtb. Our results define the complex multicellular ecosystems underlying (lack of) granuloma resolution and highlight host immune targets that can be leveraged to develop new vaccine and therapeutic strategies for TB.<br />Competing Interests: Declaration of interests A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Third Rock Ventures, Hovione, Relation Therapeutics, FL82, Empress Therapeutics, Ochre Bio, and Dahlia Biosciences.C.L. is a shareholder and consultant for Honeycomb Biotechnologies. T.K.H. is a shareholder and consultant for nference, inc.<br /> (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-4180
Volume :
55
Issue :
5
Database :
MEDLINE
Journal :
Immunity
Publication Type :
Academic Journal
Accession number :
35483355
Full Text :
https://doi.org/10.1016/j.immuni.2022.04.004